Early Change in FDG-PET Signal and Plasma Cell-Free DNA Level Predicts Erlotinib Response in EGFR Wild-Type NSCLC Patients.
BACKGROUND
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are a treatment option in the second- or third-line palliative setting in EGFR wild-type (wt) non-small cell lung cancer (NSCLC) patients. However, response rates are low, and only approximately 25% will achieve disease control. Early prediction of treatment resistance could accelerate discontinuation of ineffective treatment and reduce unnecessary toxicity. In this study, we evaluated early changes on 18F-fluoro-D-glucose (F-18-FDG) positron emission tomography/computed tomography (PET/CT) and in total plasma cell-free DNA (cfDNA) as markers of erlotinib response in EGFR-wt patients.


METHODS
F-18-FDG-PET/CT scans and blood samples were obtained prior to erlotinib initiation and were repeated after 1 week (PET/CT) and 1 to 4 weeks (blood sample) of treatment. Level of cfDNA was measured by droplet digital polymerase chain reaction. Percentage change (%∆) in SULpeakand total lesion glycolysis (TLG) on FDG-PET/CT and in plasma cfDNA was correlated to radiological response, progression-free survival (PFS), and overall survival (OS).


RESULTS
Fifty patients were prospectively enrolled. A significant correlation was found between CT response and %∆TLG (P=.003). All patients with early metabolic progression showed radiological progression. Increased %∆TLG and %∆cfDNA were significantly correlated with shorter PFS (P=.002 and P=.004, respectively) and OS (P=.009 and P=.009, respectively). Multivariate analysis indicated %∆cfDNA to be the strongest predictor of OS.


CONCLUSIONS
Early increase in TLG on F-18-FDG-PET/CT correlates with radiological progression, and shorter PFS and OS. Early increase in cfDNA predicts shorter PFS and OS. Both assessments are promising tools for early detection of nonresponders and reduced OS in TKI-treated EGFR-wt NSCLC patients.
Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark. Electronic address: anlarsen@rm.dk.
Anne
A
Winther-Larsen
Department of Nuclear Medicine, Herning Regional Hospital, Herning, Denmark.
Joan
J
Fledelius
Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark.
Christina
C
Demuth
Department of Radiology, Aarhus University Hospital, Aarhus, Denmark.
Catharina M
CM
Bylov
Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.
Peter
P
Meldgaard
Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark.
Boe S
BS
Sorensen